mhra

MHRA awards ILAP Innovation Passports to three investigational treatments

Candidates for lung cancer, Huntington’s disease and Alzheimer’s disease will receive coordinated ILAP support. A new application round closes on 11 February 2027.

Ersin ÇETİNMDR Auditor
Türkçe oku
Conceptual development pathway connecting molecular research, drug-device combinations and regulatory assessment
AI-generated conceptual illustration, not a photograph of an actual event.

What Changed

The Medicines and Healthcare products Regulatory Agency (MHRA) announced on 9 November 2026 that three investigational treatments have received Innovation Passports through the Innovative Licensing and Access Pathway (ILAP). Selection followed assessment by the ILAP Selection Panel and enables coordinated support throughout development.

The candidates are Alnylam’s brezosiran, an RNAi therapeutic for Huntington’s disease; BeOne Medicines’ BGB-58067, an investigational PRMT5 inhibitor; and Biogen’s diranersen, an antisense oligonucleotide for early Alzheimer’s disease. First-line non-small cell lung cancer is expected to be the oncology candidate’s lead indication.

Who Is Affected

The awards directly concern the three developers. The wider pathway is also relevant to commercial and non-commercial developers worldwide seeking support for innovative medicines and drug-device combinations addressing unmet patient needs.

Although drug-device combinations fall within ILAP’s scope, the three awards announced here concern investigational medicines. MHRA did not announce a separate medical-device decision.

Regulatory and Technical Implications

ILAP brings developers together with the regulator, the national health system and health technology assessment bodies from early clinical development. NICE highlighted opportunities to support evidence generation and early engagement on issues that will shape future evaluation and patient access.

All three products remain in development. Their future availability depends on evidence of safety, effectiveness and value; the announcement does not establish that they are available for patient use.

Manufacturer Actions

MHRA encourages developers of innovative medicines addressing unmet needs to review the eligibility criteria and apply. Developers of drug-device combinations should likewise consider the pathway’s scope and development-stage conditions.

Eligible medicines or drug-device combinations must not yet have entered their confirmatory trial. Prospective applicants can assess their development programmes against the eligibility conditions in MHRA’s ILAP guidance.

Confirmed Dates

The announcement was published on 9 November 2026. The next Innovation Passport application round opened that day and remains open until 11 February 2027.

No date was announced for future availability of the three treatment candidates.

Official Source

MHRA’s press release, published on GOV.UK on 9 November 2026, announces the awards and application window. ILAP partners include MHRA, NHS England, NICE, the Scottish Medicines Consortium, the All Wales Therapeutics and Toxicology Centre, and the Department of Health Northern Ireland.

Https://www.gov.uk/government/news/investigational-treatments-for-lung-cancer-huntingtons-disease-and-alzheimers-gain-innovation-passports-through-the-innovative-licensing-and-access-pa

Source and related services

Investigational treatments for lung cancer, Huntington’s disease and Alzheimer's gain Innovation Passports through the Innovative Licensing and Access Pathway ↗

Source date: 09/11/2026

This news provides general information and does not replace device-specific legal or conformity assessment advice.

Related news

MHRA sets out 2026–2027 clinical investigation fee waivers →MHRA publishes second-quarter results report for 2026–2027 →MHRA publishes field safety notices covering medical devices and diagnostics →
Contact an MDR Expert